The Manila Times

Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light C…

Single intrathecal dose of SCAD-siRNA therapeutic RAG-17 yields favorable safety profile and profound, durable biomarker ...